OKYO Pharma Reschedules KOL Event for OK-101 Phase 2 Trial Results
Ticker: OKYO · Form: 6-K · Filed: Apr 9, 2024 · CIK: 1849296
Sentiment: neutral
Topics: rescheduling, clinical-trial, event-update
TL;DR
OKYO Pharma postponed its KOL event for OK-101 Phase 2 trial results, new date TBD.
AI Summary
OKYO Pharma Ltd announced on April 8, 2024, that it is rescheduling its Key Opinion Leader (KOL) event. This event was intended to present comprehensive detailed results from the Phase 2 trial of OK-101 in Dry Eye Disease, which was originally scheduled for April 9, 2024.
Why It Matters
The rescheduling of this event may impact investor understanding of the OK-101 trial data and the company's development timeline for its dry eye disease treatment.
Risk Assessment
Risk Level: medium — Rescheduling a key event related to trial results can indicate unforeseen issues or delays, potentially impacting investor confidence and the stock price.
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- OK-101 (drug) — Drug being tested in Phase 2 trial
- Dry Eye Disease (condition) — Indication for OK-101
- April 8, 2024 (date) — Date of announcement
- April 9, 2024 (date) — Original date of KOL event
FAQ
What is the reason for rescheduling the KOL event?
The filing does not specify the reason for rescheduling the KOL event.
When was the KOL event originally scheduled?
The KOL event was originally scheduled for April 9, 2024.
What was the purpose of the KOL event?
The purpose of the KOL event was to present comprehensive detailed results from the Phase 2 trial of OK-101 in Dry Eye Disease.
What is the name of the drug being discussed?
The drug being discussed is OK-101.
What is the indication for the drug OK-101?
The indication for the drug OK-101 is Dry Eye Disease.
Filing Stats: 385 words · 2 min read · ~1 pages · Grade level 15.3 · Accepted 2024-04-08 19:00:04
Filing Documents
- form6-k.htm (6-K) — 23KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 23KB
- 0001493152-24-013975.txt ( ) — 71KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: April 8, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated April 8, 2024 4